Clinical Trial Update: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing talquetamab to belantamab mafodotin in relapsed/refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed/ Refractory Multiple Myeloma | Phase 3 | Status: WITHDRAWN